VTGN
Vistagen Therapeutics Inc.
$3.33
+$0.35(+11.74%)
72
Overall
--
Value
72
Tech
--
Quality
Market Cap
$89.28M
Volume
3.51M
52W Range
$1.90 - $3.88
Target Price
$13.00
Order:
Income Statement
| Metric | Trend | Chart | 2016 Mar | 2017 Mar | 2018 Mar | 2019 Mar | 2020 Mar | 2021 Mar | 2022 Mar | 2023 Mar | 2024 Mar | 2025 Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | -- | $1.3M | -- | -- | -- | $1.1M | $1.1M | $-227.0K | $1.1M | $486.0K | ||
| Total Revenue | -- | $1.3M | -- | -- | -- | $1.1M | $1.1M | $-227.0K | $1.1M | $486.0K | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | -- | $1.3M | -- | -- | -- | $1.1M | $1.1M | $-227.0K | $1.1M | $486.0K | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-17.9M | $-11.5M | $-14.2M | $-24.6M | $20.8M | $19.0M | $48.9M | $59.0M | $34.1M | $56.5M | ||
| Research & Development | $3.9M | $5.2M | $7.8M | $17.1M | $13.4M | $11.9M | $35.4M | $44.4M | $20.0M | $39.4M | ||
| Research Expense | $3.9M | $5.2M | $7.8M | $17.1M | $13.4M | $11.9M | $35.4M | $44.4M | $20.0M | $39.4M | ||
| Selling, General & Administrative | $13.9M | $6.3M | $6.4M | $7.5M | $7.4M | $7.1M | $13.5M | $14.7M | $14.1M | $17.1M | ||
| General & Administrative Expenses | $13.9M | $6.3M | $6.4M | $7.5M | $7.4M | $7.1M | $13.5M | $14.7M | $14.1M | $17.1M | ||
| Salaries & Wages | $-4.0M | $-851.3K | $-2.3M | $-3.4M | -- | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | $1.9M | $-54.9K | $-80.7K | $-91.2K | $103.1K | $117.6K | $153.5K | $129.5K | -- | -- | ||
| Depreciation & Amortization | $1.9M | $-54.9K | $-80.7K | $-91.2K | $103.1K | $117.6K | $153.5K | $129.5K | -- | -- | ||
| Amortization | $1.9M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Operating Expenses | $-17.9M | $-11.5M | $-14.2M | $-24.6M | $-146.0K | $-117.3K | $-156.2K | $-195.0K | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-19.7M | $-10.2M | $-14.2M | $-24.6M | $-20.8M | $-17.9M | $-47.8M | $-59.3M | $-33.0M | $-56.0M | ||
| EBITDA | $-45.9M | $-10.1M | $-14.3M | $-24.5M | $-20.3M | $-17.4M | $-47.0M | $-58.7M | $-32.1M | $-55.3M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $770.8K | $4.6K | $8.9K | $8.0K | $-30.1K | $13.0K | $-19.9K | $23.0K | $-3.4M | $-4.6M | ||
| Intinc | -- | -- | -- | -- | -- | -- | -- | $26.0K | -- | $4.6M | ||
| Net Non-Operating Interest Income/Expense | $-770.8K | $-4.6K | $-8.9K | $-8.0K | $30.1K | $1.6K | $-20.0K | $26.0K | $3.4M | $4.6M | ||
| Other Income/Expense | $26.7M | -- | $135.0K | $22.7K | -- | $-600 | $-232.0K | $77.4K | $-312.0K | $-5.0K | ||
| Other Special Charges | $-26.7M | -- | $-135.0K | $-22.7K | -- | $600 | -- | $-77.4K | $312.0K | $5.0K | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | -- | -- | -- | $-528.3K | -- | -- | ||
| Special Income Charges | -- | -- | -- | -- | -- | -- | -- | $528.3K | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-46.4M | $-10.2M | $-14.3M | $-24.6M | $-20.8M | $-17.9M | $-47.8M | $-59.3M | $-32.7M | $-56.0M | ||
| Pre-Tax Income | $-47.2M | $-10.3M | $-14.3M | $-24.6M | $-20.8M | $-17.9M | $-47.8M | $-59.2M | $-29.4M | $-51.4M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $2.3K | $2.4K | $2.4K | $2.6K | $2.6K | $2.6K | $3.4K | $6.0K | $4.0K | $7.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $-47.2M | $-10.3M | $-14.3M | $-24.6M | $-20.8M | $-17.9M | $-47.8M | $-59.2M | $-29.4M | $-51.4M | ||
| Net Income (Continuing Operations) | $-47.2M | $-10.3M | $-14.3M | $-24.6M | $-20.8M | $-17.9M | $-47.8M | $-59.2M | $-29.4M | $-51.4M | ||
| Net Income (Discontinued Operations) | $-47.2M | $-10.3M | $-14.3M | $-24.6M | $-20.8M | $-17.9M | $-47.8M | $-59.2M | $-29.4M | $-51.4M | ||
| Net Income (Common Stockholders) | $-51.4M | $-11.6M | $-15.6M | $-25.7M | $-22.0M | $-42.3M | $-48.7M | $-59.2M | $-29.4M | $-51.4M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-50.9M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-17.9M | $-11.5M | $-14.2M | $-24.6M | $20.8M | $19.0M | $48.7M | $59.0M | $34.1M | $56.5M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $58.9K | $251.1K | $463.0K | $952.1K | $1.5M | $2.9M | $6.6M | $7.0M | $19.4M | $30.9M | ||
| Average Shares Outstanding (Diluted) | $58.9K | $222.0K | $427.0K | $910.7K | $1.5M | $2.9M | $6.6M | $7.0M | $19.4M | $30.9M | ||
| Shares Outstanding | $30.7M | $310.0K | $30.7M | $1.4M | $1.9M | $6.4M | $6.9M | $7.9M | $27.0M | $29.2M | ||
| Basic EPS | $-872.4 | -- | -- | -- | $-15 | $-14.7 | $-7.5 | $-8.51 | $-1.52 | $-1.67 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-15 | $-14.7 | $-7.5 | $-8.51 | $-1.52 | $-1.67 | ||
| Diluted EPS | $-872.4 | $-46.2 | $-33.6 | $-27 | $-15 | $-14.7 | $-7.5 | $-8.51 | $-1.52 | $-1.67 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | -- | -- | $-1.52 | $-1.67 | ||
| OTHER METRICS | ||||||||||||
| Accrued Preferred Stock Dividends | $4.2M | $1.4M | $1.2M | $1.1M | $1.3M | $1.4M | $945.1K | -- | -- | -- | ||
| Acquisition Expense | -- | -- | -- | -- | -- | $23.0M | -- | -- | -- | -- | ||
| Interest Expense Operating | -- | -- | -- | -- | -- | $-13.3K | $-300 | -- | -- | -- | ||
| Net Operating Interest Income Expense | -- | -- | -- | $-8.0K | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $13.9M | $6.3M | $6.4M | $7.5M | $7.4M | $7.1M | $13.5M | $14.7M | $14.1M | $17.1M | ||
| Otherunder Preferred Stock Dividend | $4.2M | $1.4M | $1.2M | $1.1M | $1.3M | $1.4M | $945.1K | -- | -- | -- | ||
| Preferred Stock Dividends | $4.2M | $1.4M | $1.2M | $1.1M | $1.3M | $1.4M | $945.1K | -- | -- | -- | ||
| Rent And Landing Fees | $13.9M | $6.3M | $6.4M | $7.5M | $14.0K | $14.2K | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | -- | -- | -- | $-528.3K | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VTGN | $3.33 | +11.7% | 3.51M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Vistagen Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW